All News
AOSD: Young vs. Elderly Onset
Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
Read Article
ANSWER cohort
Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs
✔️IL-6Ri is the lowest discontinued for lack of efficacy
✔️CTLA4-Ig is the lowest discontinued due to AEs
✔️Concomitant GC ⬆️30% drug discontinuation due to AEs
@Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm AurelieRheumo ( View Tweet)
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8)
Use of TNFi & orthopedic implants associated w/ OAI risk
Mortality however similar in RA and non RA groups
@RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
Aurelie Najm AurelieRheumo ( View Tweet)
Always great to have @EMA_News to come and to talk to us at #EULAR2023
Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍
@RheumNow https://t.co/hSutraUsFD
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
NYU's star rheumatologist, Dr. Jose Scher, wit on the fly at #EULAR2023 https://t.co/O9afiVHSV5
Dr. John Cush RheumNow ( View Tweet)
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC?
Brief answer is no, but:
-PsA > tortuous capillaries vs. PSO & HC
-Abnormalities in PSO to be used as predictor of PsA?
TBC...
@RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Fluorescence optical imaging in early arthritis?
Nice images but not ready for clinics yet
Can not differentiate OA from RA & PsA
SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis
OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Aurelie Najm AurelieRheumo ( View Tweet)
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush RheumNow ( View Tweet)
Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh
Dr. John Cush RheumNow ( View Tweet)
🛑Doing Hands and feet Xray in undifferentiated arthritis?
Retro study 700+pts shows:
✔️only few patients w/ UA present w/ RA-associated erosions at presentation
✔️Rarely leads to change in diagnosis or prognosis.
Will you stop? I probably won't 👀
@RheumNow #EULAR23 OP0172 https://t.co/BRpmDqaN0r
Aurelie Najm AurelieRheumo ( View Tweet)
#Lupus #nephritis - many trials and this is one company #Roche and other #pharmaceutical CO’s are also involved #Hope #SLE #EULAR2023 @RheumNow @eular_org https://t.co/Giu2iUqq6j
Janet Pope Janetbirdope ( View Tweet)
The steroid dosing in SAPHYR (sarilumab in PMR):
Bottom two trajectories: sarilumab protocol & actual
Top two trajectories: placebo protocol & actual
Fascinating that with sarilumab, more PNL only really in play at PNL <3mg/d. Def takes the heat out
POS0715 #EULAR2023 @RheumNow https://t.co/aEC8cQaR7O
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH)
• Bone pain, xanthelasma, hairy kidney
• Differential diagnoses of LCH
• BRAF mutation associated with cardiac and neurological phenotype of ECD
Haroche J, Papo M
#EULAR2023
@RheumNow https://t.co/AzKJKp82nq
Dr. Antoni Chan synovialjoints ( View Tweet)
What do we do with PMR patients with subclinical GCA seen on ultrasound?
Well, in these non-blinded cohorts the subclinical GCA pts got more pred.
Was it warranted? Hard to say. If we’re going to look for it, let’s try and figure out what it means
POS0712 #EULAR2023 @RheumNow https://t.co/KmCcE0Nsu9
David Liew drdavidliew ( View Tweet)
Rx of #lupus #SLE The most challenging seems to be longstanding & residual disease activity - damage accumulates over time - esp if #glucocorticoids are used. Consider only as bridging. How to treat #lupus #EULAR2023 Boumpas @RheumNow #ClinicalPearl @eular_org https://t.co/heBbcRAjxO
Janet Pope Janetbirdope ( View Tweet)
I mean, if proteomics is more your jive for GCA, we’ve got that too here at #EULAR2023. Definite potential for phenotyping a disease with diverse outcomes
POS0694 @RheumNow https://t.co/tSWpZlUPoE
David Liew drdavidliew ( View Tweet)